학술논문
Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
Document Type
Article
Author
Qin, Simon Xiwen; Cheng, Franco Wing Tak; Kwok, Wang Chun; Fung, Lydia W. Y.; Ma, Tian Tian; Yiu, Hei Hang Edmund; Bloom, Chloe; McDonald, Christine F.; Cheung, Ching-Lung; Lai, Francisco Tsz Tsun; Chui, Celine Sze Ling; Li, Xue; Wong, Carlos King Ho; Wan, Eric Yuk Fai; Wong, Ian Chi Kei; Chan, Esther Wai Yin
Source
Subject
*COVID-19
*COVID-19 vaccines
*ASTHMATICS
*CHRONIC obstructive pulmonary disease
*PROPORTIONAL hazards models
*
*
*
*
Language
ISSN
0114-5916
Abstract
Introduction: Effectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma. Methods: Using electronic health care records in Hong Kong, we included adults with COPD or asthma or both and hospitalised for severe respiratory exacerbation in a self-controlled case series (SCCS) study between 23/02/2021 and 30/11/2022. Conditional Poisson regression models were used to estimate the incidence of outcomes within exposure periods (28 days after each dose) compared with baseline periods. Cox proportional hazard models evaluated vaccine effectiveness (VE) against COVID-related mortality, hospitalisation, and severe complications, including admission to intensive care units or ventilatory support. The VE assessment was based on vaccine types and the number of doses. Results: In the SCCS, 343 CoronaVac recipients and 212 BNT162b2 recipients were included. No increased risk of outcomes was observed within the exposure periods. In the cohort study, 108,423 and 83,323 patients received ≥ 2 doses of CoronaVac and BNT162b2, respectively. The VE (95% CI) against COVID-related mortality, hospitalisation, and severe complications after two-dose CoronaVac was 77% (74–80%), 18% (6–23%), and 29% (12–43%), respectively, while for the two-dose regimen of BNT162b2, it was 92% (91–94%), 33% (30–37%), and 57% (45–66%), respectively. Higher VE against COVID-related mortality, hospitalisation, and severe complications was found for the three-dose regimen of CoronaVac (94%, 40%, and 71%) and BNT162b2 (98%, 65%, and 83%). Administering a fourth dose of either vaccine showed additional reductions in COVID-related outcomes. Conclusions: Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves. [ABSTRACT FROM AUTHOR]